Relationship between plasma levels of lipopolysaccharide (LPS) and LPS- binding protein in patients with severe sepsis and septic shock

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1584-1589

  Opal, Steven M ^a,e   Scannon, Patrick J ^b   Vincent, Jean Louis ^c   White, Mark ^b   Carroll, Stephen F ^b   Palardy, John E ^a   Parejo, Nicolas A ^a   Pribble, John P ^a   Lemke, Jon H ^d  

^a BROWN UNIVERSITY   (United States)

^b XOMA   (United States)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY OF IOWA   (United States)

^e MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; ENDOTOXIN;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SEPTIC SHOCK; SURVIVAL;

ACUTE-PHASE PROTEINS; ADULT; AGED; BACTEREMIA; CARRIER PROTEINS; ENDOTOXINS; FEMALE; FUNGEMIA; HUMANS; LIPOPOLYSACCHARIDES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS; SHOCK, SEPTIC;

EID: 0032754358     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315093     Document Type: Article

References (45)

1. 1. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol 1996;60:8-26.
2. 2. Yang R-B, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced-cellular signalling. Nature 1998;395:284-8.
3. 3. Kirschning CJ, Weschelt, Ayres TM, Roth M. Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998; 188:2091-7.
4. 4. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57 BL/10Sc CR mice: mutations in the TLR 4 gene. Science 1998;282:2085-8.
5. 5. Qureshí ST, Lariviere L, Leveque G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (TLR4). J Exp Med 1999;189:615-25.
6. 6. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274: 10689-92.
7. 7. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-69.
8. 8. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
9. 9. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-7.
10. 10. daSilva AMT, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple organ dysfunction after self administration of Salmonella endotoxin. N Engl J Med 1993;328:1457-60.
11. 11. Novitsky TJ. Limulus amebocyte lysate (LAL) detection of endotoxin in human blood. J Endotoxin Res 1994;1:253-63.
12. 12. Roslansky PF, Novitsky TJ. Sensitivity of Limulus amebocyte lysate (LAL) to LAL-reactive glucans. J Clin Microbiol 1991;29:2477-83.
13. 13. Hurley JC. Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev 1995;8:268-92.
14. 14. van Deventer SJH, Buller HR, tenCate JW, Sturk A, Paw W. Endotoxemia: an early predictor of septicaemia in febrile patients. Lancet 1988;1:605-8.
15. 15. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest 1991;99:169-75.
16. 16. Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of gram-negative septic shock with an immunoglobulin preparation:a prospective, randomized clinical trial. Crit Care Med 1991;19:1104-13.
17. 17. Wortel CH, von der Möhlen MAM. van Deventer SJH, et al. Effectiveness of human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 1992; 166:1367-74.
18. 18. Parsons PE, Worther GS, Moore EE, Tate RM, Henson PM. The association of circulating endotoxin with the development of the adult respiratory distress syndrome. Am Rev Respir Dis 1989;140:294-301.
19. 19. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 1993;119:771-8.
20. 20. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-83.
21. 21. Hurley JC. Concordance of endotoxemia with gram-negative bacteremia in patients with gram-negative sepsis: a meta-analysis. J Clin Microbiol 1994;32:2120-7.
22. 22. Opal SM, Marra MN, McKelligan B, Fisher CJ, Palardy JE, Scott R. Relative concentrations of endogenous endotoxin binding proteins in infected body fluids. Lancet 1994;344:429-31.
23. 23. Fenton MJ, Golenbock DT. LPS-binding protein and receptors. J Leukoc Biol 1998;64(1):25-32.
24. 24. Wurfel MM, Monks BG, Ingalls RR, et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med 1997;186(12):2051-6.
25. 25. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 1997;389:742-5.
26. 26. Lamping, N, Dettmer R, Schroder, NWJ, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998;101:2065-71.
27. 27. Dedrick RL, Huang K, Wu H-M, White M, Ammons S. Elevated levels of lipopolysaccharide (LPS) binding protein (LBP reduce the inflammatory potential of LPS in vitro and in vivo. J Endotoxin Res 1996;3(Suppl 1): 18.
28. 28. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem 1996;271(8): 4100-5.
29. 29. Tapping RI, Tobias PS. Cellular binding of soluble CD14 requires lipopolysaccharide (LPS) and LPS-binding protein. J Biol Chem 1997;272: 23157-64.
30. 30. Fisher CJ Jr., Dhainaut J-F, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist reduces mortality of patients with sepsis syndrome as a function of severity: a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
31. 31. Bone RC, Balk RA, Cerra FB, et al. The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis in organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;28:864-74.
32. 32. Redl H, Bahrami S, Leichtfried G, Schlag G. Special collection and storage tubes for blood endotoxin and cytokine measurements. Clin Chem 1992;38:764-5.
33. 33. Novitsky TJ, Roslansky PF, Siber GR, Warren HS. Turbidimetric method for quantifying serum inhibition of limulus amebocyte lysate. J Clin Microbiol 1985;21:211-6.
34. 34. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utime JG. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987;93:832-7.
35. 35. Teteda K, Motsumoto T, Miyazaki S, Yamaguchi K. Lipopolysaccharide-induced lethality and cytokine production in aged mice. Infect Immun 1996;64:769-75.
36. 36. Kirschning CJ, Unbehaun A, Fiedler G, et al. The transcriptional activation pattern of lipopolysaccharide binding protein (LBP) involving transcription factors AP-1 and C/EBP beta. Immunobiology 1997;198:124-35.
37. 37. Carroll SF, Dedrick L, White ML. Plasma Levels of Lipopolysaccharide binding protein (LBP) correlate with outcome in sepsis and other patients [abstract 101]. In: Abstracts of the Sixth Vienna Shock Forum. Vienna, Austria: 8-11 November 1997.
38. 38. Schumann RR, Zweigner J, Lamping N, Gramm HJ. Significantly elevated levels of lipopolysaccharide binding protein (LBP) in patients with severe sepsis: a prospective cohort study with 109 surgical ICU patients [abstract LB17]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans: 15 September 1996.
39. 39. Lengacher S, Jongencel CV, Le Roy D, et al. Reactivity of murine and human recombinant LPS binding protein (LBP) with LPS and gram-negative bacteria. J Inflamm 1995-96;47:165-72.
40. 40. Troelstra A, Giepmans BN, Van Kessel KP, Lichenstein HS, Verhoef J, Van Strijp JA. Dual effects of soluble CD14 on LPS priming of neutrophils. J Leukoc Biol 1997;61:173-8.
41. 41. Liao W, Florén C-H. Hyperlipidemic response to endotoxin - a part of the host defense mechanism. Scand J Infect Dis 1993;25:675-82.
42. 42. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine antagonists and endogenous anti-endotoxin core antibodies in sepsis syndrome. JAMA 1995;274:172-7.
43. 43. Nys M, Damas P, Joassin L, Lamy M. Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome. Ann Surg 1993;217:300-6.
44. 44. Stüber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome in patients with severe sepsis. Crit Care Med 1996;24:381-4.
45. 45. Labata MO, Durieux J-J, Spangnoli G, Fernandez N, Wijdenes J, Herrmann D. CD14 and tolerance to lipopolysaccharide: biochemical and functional analysis. Immunology 1993;80:415-23.